90befe3158
Pentagon-Agent: Vida <HEADLESS>
4.2 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | Psychiatric Adverse Events Linked to GLP-1 Analogues: A Disproportionality Analysis in American, Canadian and Australian Adverse Event Databases | PMC (multiple authors) | https://pmc.ncbi.nlm.nih.gov/articles/PMC12630159/ | 2025-01-01 | health | paper | unprocessed | medium |
|
research-task |
Content
Cross-national pharmacovigilance disproportionality analysis using three national adverse event databases: FAERS (US), Canada Vigilance Adverse Reaction Online Database (CVAROD), and Database of Adverse Event Notifications (DAEN, Australia).
Key findings on eating disorders:
- Dulaglutide in FAERS: ROR = 1.47 (95%CI 1.26-1.71)
- Dulaglutide in DAEN (Australia): ROR = 17.66 (95%CI 2.45-127.37) — extremely elevated
- Tirzepatide in FAERS: ROR = 1.58 (95%CI 1.14-2.20)
- Note: Lower values than VigiBase study — reflects different database populations, denominator calculations, and the fact that this is US/CA/AU only vs. global VigiBase
Indication bias explicitly acknowledged: "The databases used in this study did not contain information on any pre-existing psychiatric conditions in patients reporting AEs" — researchers could not "distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues"
Causality conclusion: Researchers "cannot determine a causal relationship between medication use and AEs" — results should be "interpreted with caution and supplemented with clinical studies to confirm associations"
Agent Notes
Why this matters: Confirms the eating disorder signal across US, Canadian, and Australian databases — the signal isn't US-specific or FAERS-specific. The Australian DAEN result (ROR 17.66 for dulaglutide) is particularly high, suggesting the signal may be even stronger in populations where dulaglutide has higher relative prescribing share. The cross-national consistency increases biological plausibility.
What surprised me: The ROR values here (1.47-1.58) are MUCH lower than the VigiBase aROR (4.17-6.80). This discrepancy is methodologically significant: VigiBase uses adjusted analysis (aROR controls for co-reported adverse events) while this study may not. The VigiBase analysis is the more reliable estimate — but the discrepancy between studies is itself a finding that an extractor should note.
What I expected but didn't find: CVAROD (Canadian) results for eating disorders — the paper either didn't find a significant signal there or the abstract/summary I accessed didn't report it.
KB connections:
- AI diagnostic triage achieves 97 percent sensitivity — parallel: pharmacovigilance databases have the same "signal vs. noise" sensitivity-specificity tradeoff
- healthcare AI regulation needs blank-sheet redesign — pharmacovigilance methodology also needs redesign for medication classes with behavioral effects
Extraction hints: Useful as CORROBORATING evidence for the VigiBase signal across additional databases. The Australian DAEN outlier (ROR 17.66) deserves specific mention — possible explanation is small denominator, different population, or higher awareness/reporting in Australia. NOT sufficient as a standalone source for the eating disorder claim — use alongside VigiBase as supporting evidence.
Context: This is a methodologically weaker study than the VigiBase analysis but provides geographic breadth. The indication bias limitation is shared by all pharmacovigilance databases.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 WHY ARCHIVED: Corroborating cross-national evidence for the eating disorder pharmacovigilance signal — extractor should use as secondary evidence, not primary EXTRACTION HINT: Flag the discrepancy between this study's ROR (1.47-1.58) and VigiBase's aROR (4.17-6.80) in any claims that cite both — the methodological difference matters.